Harlan Laboratories Contract Research Services (CRS) has launched a dedicated Translational Medicine program aimed at speeding drug development, minimizing late-stage risk of failure, and reducing costs. The company will combine its expertise in metabolic profiling, genotoxicity, skin penetration, immunology, pharmacology and bioproducts, with its knowledge of regulatory requirements, to offer a range of screening and modeling packages to help to detect signals of toxicity, efficacy and unwanted...